Cancer Research UK
275
40
62
115
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
10.9%
30 terminated/withdrawn out of 275 trials
79.3%
-7.3% vs industry average
14%
39 trials in Phase 3/4
22%
25 of 115 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (275)
HTL0039732 in Participants With Advanced Solid Tumours
Role: lead
WIRE - Novel Treatments in Renal Cell Cancer
Role: collaborator
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
Role: collaborator
Understanding New Cachexia Subtypes Through Observational Epidemiological Research
Role: collaborator
A Phase I Trial of LY3143921 Hydrate in Solid Tumours
Role: lead
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Role: lead
5G-EMERALD: Amivantamab in Malignant Brain Tumours
Role: collaborator
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Role: collaborator
TT-702 in Patients With Advanced Solid Tumours.
Role: lead
UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies
Role: collaborator
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Role: collaborator
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
Role: collaborator
Using Patient Navigation to Promote Bowel Screening in AAA Attendees.
Role: collaborator
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Role: collaborator
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
Role: collaborator
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Role: lead
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
Role: collaborator
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
Role: collaborator
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Role: collaborator
SCOOT: Sample Collection for DART
Role: collaborator